Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (21519)	5/28/1998 5:25:00 PM
From: Lyn Benson	Read Replies (1) \| Respond to of 32384

Can anyone familiar with P & F offer an interpretation of the chart? I am fairly new at it but it looks to be in a significant uptrend with a potential of hitting previous heights of 18-20. Where is the King of France when you need him? <g>

To: Hippieslayer who wrote (21519)	5/28/1998 6:34:00 PM
From: Henry Niman	Respond to of 32384

LGND's news was carried in WSJ: The Wall Street Journal -- May 28, 1998 Ligand Pharmaceuticals Inc. SAN DIEGO -- Ligand Pharmaceuticals Inc. said it filed its first new-drug application with the Food and Drug Administration, an important milestone for the drug development company. The FDA filing is for Panretin gel, a topical therapy for Kaposi's sarcoma, a cancer common in people who have AIDS. "We are very pleased that, if approved, Panretin gel will offer a new, less invasive and less toxic alternative therapy to people with AIDS-related KS," said David E. Robinson, Ligand chairman, president, and chief executive officer. The FDA filing is based on human tests conducted in Europe, Australia and North America.

To: Hippieslayer who wrote (21519)	5/28/1998 8:38:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Here's what Dow Jones said about yesterday's press release: Dow Jones Newswires -- May 27, 1998 Ligand Files NDA For Panretin Gel In Kaposi's Sarcoma SAN DIEGO (Dow Jones)--Ligand Pharmaceuticals Inc. (LGND) submitted a new drug application to the Food and Drug Administration for Panretin gel, its AIDS-related Kaposi's sarcoma topical treatment. As reported March 26, the pharmaceutical company said final analysis of its Phase III pivotal trial data indicated 37.1% of patients treated with Panretin gel experienced complete or partial response compared with 6.9% of patients using a placebo.

To: Hippieslayer who wrote (21519)	5/28/1998 8:41:00 PM
From: Henry Niman	Respond to of 32384

Here's what DJ had to say about today's press release: Dow Jones Newswires -- May 28, 1998 Ligand Pharma Pays $4.1M Fee To Salk Institute After NDA SAN DIEGO (Dow Jones)--Ligand Pharmaceuticals Inc. (LGND) exercised its option to pay a one-time, $4,080,000 fee to the Salk Institute for Biological Studies, in connection with Ligand's filing a New Drug Application with the Food and Drug Administration for a Kaposi's sarcoma treatment. In a press release Thursday, Ligand said the payment gives it a fully paid up license for the patent rights to Panretin gel under its 1988 agreement with the Salk Institute. As reported Wednesday, Ligand filed an NDA for Panretin gel (alitretinoin) 0.1% for as a topical treatment for AIDS-related Kaposi's sarcoma. The Salk Institute for Biological Studies, La Jolla, Calif., is an independent nonprofit institution that primarily conducts research in neuroscience and molecular biology and genetics.